Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript

Core Viewpoint - Aldeyra Therapeutics announced an extension of the PDUFA target action date for the new drug application of reproxalap, which is intended for the treatment of dry eye disease [2]. Group 1: Regulatory Update - The press release regarding the PDUFA extension is available on Aldeyra's website, emphasizing the importance of reviewing it alongside the prepared remarks from the conference call [2]. - Dr. Todd Brady, President and CEO of Aldeyra, is present to discuss the implications of the PDUFA extension for reproxalap [3].